BCR::ABL1 (Philadelphia chromosome–positive [Ph+]) ALL

Source: Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 21, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Relapsed Childhood ALL / Standard Treatment Options for First Bone Marrow Relapse of Childhood ALL / Postreinduction therapy for patients achieving a second complete remission

There is limited information regarding the treatment of patients with relapsed BCR::ABL1 ALL in the era of tyrosine kinase inhibitors (TKIs).

A French multi-institutional study reported on 27 children with relapsed BCR::ABL1 ALL (24 overt, 3 molecular) who had all been initially treated with a regimen that included imatinib.[73][Level of evidence C1]

Source links and citations

Among patients treated with either an intensive or nonintensive induction regimen, 96% obtained a second CR.

Approximately one-half of the patients received consolidation therapy, and 78% of the patients proceeded to allogeneic HSCT.

At the time of relapse, the TKI was changed for 23 of the 26 (88%) patients, 15 of whom (58%) received dasatinib. The 4-year EFS rate was 60.9%, and the OS rate was 76.1%.

Publication references

Read the original reference and check its publication notices.

PubMed 34854546 · Original source

Preserved source evidence · Not medical advice